You just read:

TapImmune Reaches 50% Patient Enrollment Benchmark in Phase 2 Study of Novel T-Cell Vaccine Targeting Triple-Negative Breast Cancer

News provided by

TapImmune Inc.

Jun 27, 2017, 09:15 ET